Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 18:12:1758835919897537.
doi: 10.1177/1758835919897537. eCollection 2020.

PARP inhibitor combinations in prostate cancer

Carmel Pezaro  1
Affiliations
Review

PARP inhibitor combinations in prostate cancer

Carmel Pezaro. Ther Adv Med Oncol. .

Abstract

Polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors cause deoxyribonucleic acid (DNA) damage that can be lethal to cells with deficient repair mechanisms. A number of PARP inhibitors are being tested as treatments for men with prostate cancer, both as monotherapies and in combinations that are based on purported synergies in treatment effect. While the initial single-agent development focused on men with identified deficiencies in DNA-repair pathways, broader patient populations are being considered for combination approaches. This review summarizes the current clinical development of PARP inhibitors and explores the rationale for novel combination strategies.

Keywords: DNA-damage repair; PARP combinations; PARP inhibitor; prostate cancer; synthetic lethality.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr Pezaro has received honoraria from Ipsen, Astellas, Mundipharma, AstraZeneca and Pfizer. Education support has been provided by Janssen.

References

    1. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 2005; 577: 275–283. - PubMed
    1. Teo MY, Bambury RM, Zabor EC, et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Cancer Res 2017; 23: 3610–3618. - PMC - PubMed
    1. Steinberger AE, Cotogno P, Ledet EM, et al. Exceptional duration of radium-223 in prostate cancer with a BRCA2 mutation. Clin Genitourin Cancer 2017; 15: e69–e71. - PubMed
    1. Crumbaker M, Emmett L, Horvath LG, et al. Exceptional response to 177Lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects. JCO Precis Oncol 2019; 3: 1–5. - PubMed
    1. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011; 5: 387–393. - PMC - PubMed

LinkOut - more resources